126 related articles for article (PubMed ID: 20798117)
1. Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
Biernacka EK; Hoffman P
Europace; 2011 Jan; 13(1):129-30. PubMed ID: 20798117
[No Abstract] [Full Text] [Related]
2. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
4. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
[No Abstract] [Full Text] [Related]
5. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
Padfield GJ; AlAhmari L; Lieve KV; AlAhmari T; Roston TM; Wilde AA; Krahn AD; Sanatani S
Heart Rhythm; 2016 Feb; 13(2):609-13. PubMed ID: 26416620
[No Abstract] [Full Text] [Related]
6. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
[TBL] [Abstract][Full Text] [Related]
7. Catecholaminergic polymorphic ventricular tachycardia.
Leenhardt A; Denjoy I; Guicheney P
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
[No Abstract] [Full Text] [Related]
8. Paroxysmal bidirectional ventricular tachycardia with tachycardiomyopathy in a pregnant woman.
Walker NL; Cobbe SM; McGavigan AD
Acta Cardiol; 2009 Jun; 64(3):419-22. PubMed ID: 19593958
[TBL] [Abstract][Full Text] [Related]
9. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
[TBL] [Abstract][Full Text] [Related]
10. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
11. [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
Le Davay M; Victor J; Dupuis JM; Merheb M; Tran P; Tadeï A
Ann Cardiol Angeiol (Paris); 1994 May; 43(5):253-5. PubMed ID: 8074416
[TBL] [Abstract][Full Text] [Related]
12. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Jacquemart C; Ould Abderrahmane F; Massin MM
J Electrocardiol; 2012; 45(6):736-8. PubMed ID: 22672791
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Vaksmann G; Klug D
Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
[TBL] [Abstract][Full Text] [Related]
14. Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
van der Werf C; Wilde AA
Europace; 2011 Jan; 13(1):11-3. PubMed ID: 20851823
[No Abstract] [Full Text] [Related]
15. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
Rienstra M; Wiesfeld AC; van Veldhuisen DJ; van Gelder IC
Ned Tijdschr Geneeskd; 2006 May; 150(18):1027-31. PubMed ID: 16715868
[TBL] [Abstract][Full Text] [Related]
16. Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations.
Napolitano C
Heart Rhythm; 2016 Feb; 13(2):614-5. PubMed ID: 26498259
[No Abstract] [Full Text] [Related]
17. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
Hong RA; Rivera KK; Jittirat A; Choi JJ
Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
[TBL] [Abstract][Full Text] [Related]
18. Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Liu N; Napolitano C; Venetucci LA; Priori SG
Trends Cardiovasc Med; 2012 Feb; 22(2):35-9. PubMed ID: 22867967
[TBL] [Abstract][Full Text] [Related]
19. [Supraventricular extrasystole after cardioversion with amiodarone].
Meinertz T
Dtsch Med Wochenschr; 2012 Jul; 137(28-29):1475. PubMed ID: 22760409
[No Abstract] [Full Text] [Related]
20. [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
Tonet J; Hidden F; Naditch L; Coutte R; Himbert C; Frank R
Ann Cardiol Angeiol (Paris); 1996 Jan; 45(1):18-23. PubMed ID: 8815771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
